{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-23-000112","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.412640+00:00","generated_at":"2026-06-11T12:23:01.303270+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Humacyte Q2 net loss $22.7M; vascular trauma trial enrollment complete, BLA on track","bullets":["Completed enrollment in Phase 2/3 V005 trauma trial (68 patients, 51 for efficacy); top-line results expected Q3 2023.","BLA filing for HAV in vascular trauma planned Q4 2023; received RMAT designation in May 2023.","Cash $114.6M; up to $160M Oberland funding ($40M received); funds operations past potential approval.","Net loss $22.7M vs net income $36.9M in Q2 2022; increase due to non-cash remeasurement of contingent earnout.","Ukraine humanitarian program: 19 patients, 95% 30-day patency, 100% limb salvage, 0 infections."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-23-000112","json":"https://secwatch.observer/filing/0001818382-23-000112.json","markdown":"https://secwatch.observer/filing/0001818382-23-000112.md","text":"https://secwatch.observer/filing/0001818382-23-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000112/0001818382-23-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000112/huma-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:23:01.303270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"813567c547a92610b011efc202281735d15789fe","claim":"Humacyte, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000112/0001818382-23-000112-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}